Yahoo Finance • 11 hours ago
BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story
Yahoo Finance • 17 days ago
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis (PRAX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Praxis and would like to discus... Full story
Yahoo Finance • 23 days ago
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX). Such investors are advised to contact Danielle Pe... Full story
Yahoo Finance • 28 days ago
BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS)... Full story
Yahoo Finance • 29 days ago
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (NASDAQ:PRAX), Align Technology, In... Full story
Yahoo Finance • last month
BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story
Yahoo Finance • last month
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its partici... Full story
Yahoo Finance • last month
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyt... Full story
Yahoo Finance • 2 months ago
Investing.com - Piper Sandler has reiterated an Overweight rating and $270.00 price target on Praxis Precision Medicines Inc . (NASDAQ:PRAX), currently trading at $45.94, following positive Phase 2 RADIANT FOS data. According to Investing... Full story
Yahoo Finance • 2 months ago
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyt... Full story
Yahoo Finance • 2 months ago
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Praxis Precision Medicines, Inc. (“Praxis” or “the Company”) (NASDAQ:... Full story
Yahoo Finance • 2 months ago
Investing.com - Wedbush raised its price target on Praxis Precision Medicines Inc . (NASDAQ:PRAX) to $33.00 from $28.00 on Monday, while maintaining an Underperform rating on the stock. According to InvestingPro data, PRAX’s stock has sho... Full story
Yahoo Finance • 2 months ago
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset... Full story
Yahoo Finance • 2 months ago
PRAXIS PRECISION MEDICINES (NASDAQ:PRAX) REPORTS Q2 2025 RESULTS AMID POSITIVE CLINICAL TRIAL DATA Praxis Precision Medicines (NASDAQ:PRAX [https://www.chartmill.com/stock/quote/PRAX]) reported its second-quarter 2025 financial results al... Full story
Yahoo Finance • 2 months ago
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational... Full story
Yahoo Finance • 3 months ago
[Brain model with neuron and receptor] dem10/iStock via Getty Images * Praxis Precision Medicines (NASDAQ:PRAX [https://seekingalpha.com/symbol/PRAX]) said that the U.S. FDA has given breakthrough therapy status to Relutrigine, a treatm... Full story
Yahoo Finance • 3 months ago
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Darden Restaurants, Inc. (Symbol: DRI), where a total volume of 7,290 contracts has been traded thus far today, a contrac... Full story
Yahoo Finance • 3 months ago
Investing.com -- Prax Group, the owner of the Lindsey oil refinery in Lincolnshire, has entered insolvency proceedings, putting hundreds of jobs at risk, according to Sky News report on Monday. State Oil, the parent company of Prax Group,... Full story
Yahoo Finance • 6 months ago
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story
Yahoo Finance • 6 months ago
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story